The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-β signaling

The leukotriene receptor antagonist pranlukast can reduce airway inflammation and remodeling by inhibiting TGF-β/Smad signaling in an OVA-sensitized and -challenged asthma mouse model, thus suppressing AHR.